Abstract
Summary
Liposomal bupivacaine has been approved by the US Food and Drug Administration for local infiltration for pain relief after bunionectomy and hemorrhoidectomy.
LPI (LP Information)' newest research report, the “Liposomal Bupivacaine Industry Forecast” looks at past sales and reviews total world Liposomal Bupivacaine sales in 2022, providing a comprehensive analysis by region and market sector of projected Liposomal Bupivacaine sales for 2023 through 2029. With Liposomal Bupivacaine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liposomal Bupivacaine industry.
This Insight Report provides a comprehensive analysis of the global Liposomal Bupivacaine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liposomal Bupivacaine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Liposomal Bupivacaine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liposomal Bupivacaine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liposomal Bupivacaine.
The global Liposomal Bupivacaine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Liposomal Bupivacaine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Liposomal Bupivacaine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Liposomal Bupivacaine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Liposomal Bupivacaine players cover Pacira Pharmaceuticals. etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Liposomal Bupivacaine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
20ml
10ml
Segmentation by application
Veterinary
Human
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pacira Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Liposomal Bupivacaine market?
What factors are driving Liposomal Bupivacaine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Liposomal Bupivacaine market opportunities vary by end market size?
How does Liposomal Bupivacaine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Liposomal Bupivacaine Industry Forecast” looks at past sales and reviews total world Liposomal Bupivacaine sales in 2022, providing a comprehensive analysis by region and market sector of projected Liposomal Bupivacaine sales for 2023 through 2029. With Liposomal Bupivacaine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liposomal Bupivacaine industry.
This Insight Report provides a comprehensive analysis of the global Liposomal Bupivacaine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liposomal Bupivacaine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Liposomal Bupivacaine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liposomal Bupivacaine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liposomal Bupivacaine.
The global Liposomal Bupivacaine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Liposomal Bupivacaine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Liposomal Bupivacaine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Liposomal Bupivacaine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Liposomal Bupivacaine players cover Pacira Pharmaceuticals. etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Liposomal Bupivacaine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
20ml
10ml
Segmentation by application
Veterinary
Human
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pacira Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Liposomal Bupivacaine market?
What factors are driving Liposomal Bupivacaine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Liposomal Bupivacaine market opportunities vary by end market size?
How does Liposomal Bupivacaine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Liposomal Bupivacaine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Liposomal Bupivacaine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Liposomal Bupivacaine by Country/Region, 2018, 2022 & 2029
2.2 Liposomal Bupivacaine Segment by Type
2.2.1 20ml
2.2.2 10ml
2.3 Liposomal Bupivacaine Sales by Type
2.3.1 Global Liposomal Bupivacaine Sales Market Share by Type (2018-2023)
2.3.2 Global Liposomal Bupivacaine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Liposomal Bupivacaine Sale Price by Type (2018-2023)
2.4 Liposomal Bupivacaine Segment by Application
2.4.1 Veterinary
2.4.2 Human
2.5 Liposomal Bupivacaine Sales by Application
2.5.1 Global Liposomal Bupivacaine Sale Market Share by Application (2018-2023)
2.5.2 Global Liposomal Bupivacaine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Liposomal Bupivacaine Sale Price by Application (2018-2023)
3 Global Liposomal Bupivacaine by Company
3.1 Global Liposomal Bupivacaine Breakdown Data by Company
3.1.1 Global Liposomal Bupivacaine Annual Sales by Company (2018-2023)
3.1.2 Global Liposomal Bupivacaine Sales Market Share by Company (2018-2023)
3.2 Global Liposomal Bupivacaine Annual Revenue by Company (2018-2023)
3.2.1 Global Liposomal Bupivacaine Revenue by Company (2018-2023)
3.2.2 Global Liposomal Bupivacaine Revenue Market Share by Company (2018-2023)
3.3 Global Liposomal Bupivacaine Sale Price by Company
3.4 Key Manufacturers Liposomal Bupivacaine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Liposomal Bupivacaine Product Location Distribution
3.4.2 Players Liposomal Bupivacaine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Liposomal Bupivacaine by Geographic Region
4.1 World Historic Liposomal Bupivacaine Market Size by Geographic Region (2018-2023)
4.1.1 Global Liposomal Bupivacaine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Liposomal Bupivacaine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Liposomal Bupivacaine Market Size by Country/Region (2018-2023)
4.2.1 Global Liposomal Bupivacaine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Liposomal Bupivacaine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Liposomal Bupivacaine Sales Growth
4.4 APAC Liposomal Bupivacaine Sales Growth
4.5 Europe Liposomal Bupivacaine Sales Growth
4.6 Middle East & Africa Liposomal Bupivacaine Sales Growth
5 Americas
5.1 Americas Liposomal Bupivacaine Sales by Country
5.1.1 Americas Liposomal Bupivacaine Sales by Country (2018-2023)
5.1.2 Americas Liposomal Bupivacaine Revenue by Country (2018-2023)
5.2 Americas Liposomal Bupivacaine Sales by Type
5.3 Americas Liposomal Bupivacaine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Liposomal Bupivacaine Sales by Region
6.1.1 APAC Liposomal Bupivacaine Sales by Region (2018-2023)
6.1.2 APAC Liposomal Bupivacaine Revenue by Region (2018-2023)
6.2 APAC Liposomal Bupivacaine Sales by Type
6.3 APAC Liposomal Bupivacaine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Liposomal Bupivacaine by Country
7.1.1 Europe Liposomal Bupivacaine Sales by Country (2018-2023)
7.1.2 Europe Liposomal Bupivacaine Revenue by Country (2018-2023)
7.2 Europe Liposomal Bupivacaine Sales by Type
7.3 Europe Liposomal Bupivacaine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Liposomal Bupivacaine by Country
8.1.1 Middle East & Africa Liposomal Bupivacaine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Liposomal Bupivacaine Revenue by Country (2018-2023)
8.2 Middle East & Africa Liposomal Bupivacaine Sales by Type
8.3 Middle East & Africa Liposomal Bupivacaine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Liposomal Bupivacaine
10.3 Manufacturing Process Analysis of Liposomal Bupivacaine
10.4 Industry Chain Structure of Liposomal Bupivacaine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Liposomal Bupivacaine Distributors
11.3 Liposomal Bupivacaine Customer
12 World Forecast Review for Liposomal Bupivacaine by Geographic Region
12.1 Global Liposomal Bupivacaine Market Size Forecast by Region
12.1.1 Global Liposomal Bupivacaine Forecast by Region (2024-2029)
12.1.2 Global Liposomal Bupivacaine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Liposomal Bupivacaine Forecast by Type
12.7 Global Liposomal Bupivacaine Forecast by Application
13 Key Players Analysis
13.1 Pacira Pharmaceuticals
13.1.1 Pacira Pharmaceuticals Company Information
13.1.2 Pacira Pharmaceuticals Liposomal Bupivacaine Product Portfolios and Specifications
13.1.3 Pacira Pharmaceuticals Liposomal Bupivacaine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pacira Pharmaceuticals Main Business Overview
13.1.5 Pacira Pharmaceuticals Latest Developments
14 Research Findings and Conclusion